During the last session, Atara Biotherapeutics Inc (NASDAQ:ATRA)’s traded shares were 0.45 million, with the beta value of the company hitting 0.49. At the end of the trading day, the stock’s price was $16.35, reflecting an intraday gain of 15.47% or $2.19. The 52-week high for the ATRA share is $39.50, that puts it down -141.59 from that peak though still a striking 60.24% gain since the share price plummeted to a 52-week low of $6.50. The company’s market capitalization is $94.17M, and the average intraday trading volume over the past 10 days was 0.11 million shares, and the average trade volume was 102.72K shares over the past three months.

Atara Biotherapeutics Inc (ATRA) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 1.40. ATRA has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.34.

Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information

Atara Biotherapeutics Inc (ATRA) registered a 15.47% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 15.47% in intraday trading to $16.35, hitting a weekly high. The stock’s 5-day price performance is 25.96%, and it has moved by 28.54% in 30 days. Based on these gigs, the overall price performance for the year is 48.64%. The short interest in Atara Biotherapeutics Inc (NASDAQ:ATRA) is 0.64 million shares and it means that shorts have 7.11 day(s) to cover.

The consensus price target of analysts on Wall Street is $14, which implies a decrease of -16.79% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $18 respectively. As a result, ATRA is trading at a discount of -10.09% off the target high and 38.84% off the low.

Atara Biotherapeutics Inc (ATRA) estimates and forecasts

Statistics show that Atara Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Atara Biotherapeutics Inc (ATRA) shares have gone up 97.46% during the last six months, with a year-to-date growth rate more than the industry average at 84.89% against 16.80. In the rating firms’ projections, revenue will increase 1,331.15% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 33.09M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 37.35M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 4.25M and 27.36M respectively. In this case, analysts expect current quarter sales to grow by 678.34% and then jump by 36.53% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 13.12%. While earnings are projected to return 88.26% in 2025.

ATRA Dividends

Atara Biotherapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Atara Biotherapeutics Inc (NASDAQ:ATRA)’s Major holders

Atara Biotherapeutics Inc insiders own 22.15% of total outstanding shares while institutional holders control 50.82%, with the float percentage being 65.29%. BOXER CAPITAL, LLC is the largest shareholder of the company, while 67.0 institutions own stock in it. As of 2024-06-30, the company held over 0.17 million shares (or 0.1181% of all shares), a total value of $1.41 million in shares.

The next largest institutional holding, with 11000.0 shares, is of LAKE STREET ADVISORS GROUP, LLC’s that is approximately 0.0078% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $93500.0.